NCEP/Framingham risk scores: Estimate of 10-yr CHD risk in men without CHD VBWG Age (y) 20–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 Points –9 –4 0 3 6 8 10 11 12 13 Age (y) 20–39 40–49 50–59 60–69 70–79 Nonsmoker 0 0 0 0 0 Smoker 8 5 3 1 1 Points Total-C Age (y) (mg/dL) 20–39 40–49 50–59 60–69 70–79 <160 0 0 0 0 0 160–199 4 3 2 1 0 200–239 7 5 3 1 0 240–279 9 6 4 2 1 ≥280 11 8 5 3 1 Systolic BP Points (mm Hg) Untreated Treated <120 0 0 120–129 0 1 130–139 1 2 140–159 1 2 ≥160 2 3 HDL-C (mg/dL) Points ≥60 –1 50–59 0 40–49 1 <40 2 Point total: <0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 >17 10-yr risk (%) <1 1 1 1 1 1 2 2 3 4 5 6 8 10 12 16 20 25 ≥30 Reilly MP, Rader DJ. Circulation. 2003;108:1546-51.

ATP III update: LDL-C goals and cutpoints for treatment VBWG Risk category LDL-C goal Initiate TLC Consider drug therapy High risk: CHD or CHD risk <100 mg/dL ≥100 mg/dL ≥100 mg/dL equivalents* (10-yr risk >20%) Moderately high risk: 2+ risk factors <130 mg/dL ≥130 mg/dL ≥130 mg/dL (10-yr risk 10%–20%) Moderate risk‡: 2+ risk factors <130 mg/dL ≥130 mg/dL ≥160 mg/dL (10-yr risk <10%) Lower risk‡: 0–1 risk factors <160 mg/dL ≥160 mg/dL ≥190 mg/dL (160–189 mg/dL drugs optional) (optional goal: <70 mg/dL)† (<100 mg/dL; consider drug options) (optional goal: <100 mg/dL) (100–129 mg/dL; consider drug options) *Diabetes or other noncoronary atherosclerotic disease †Favored for very high-risk subset ‡No changes in moderate and lower-risk category TLC = therapeutic lifestyle change Grundy SM et al. Circulation. 2004;110:227-39.